Our team of experienced Business Development experts are assisting the CEO of NUAgo Therapeutics with an undisclosed funding round.
NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues.
Our team of experienced Business Development experts are assisting the CEO of Pristine Surgical with an undisclosed funding round.
Pristine Surgical is a medical device company with a mission to simplify endoscopy. The company combines single-use endoscopes with cloud-based software to make minimally invasive visualization more efficient, consistent, and safe. Pristine Surgical offers a subscription business model with transparent pricing and automated inventory management, delivering improved workflow and reduced costs to the endoscopy suite.
Our team of experienced Business Development experts are assisting the CEO of Mermaid with an undisclosed funding round.
Pioneering intrabody-based precision medicine.
Mermaid Bio’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects.
Our team of experienced Business Development experts are assisting the CEO of NKILT Therapeutics with an undisclosed funding round.
NKILT Therapeutics is a new cell therapy biotech developing a novel approach to engineering immune cells, starting with natural killer (NK) cells, to directly target leukemias and solid tumors.
Our team of experienced Business Development experts are assisting the CEO of Preci-Health with an undisclosed funding round.
Preci-Health is revolutionizing the landscape of medical care by providing accessible, safe and virtually painless solutions for blood sampling and injections – anytime, anywhere
Our team of experienced Business Development experts are assisting the CEO of Cancer Research and Biotechnology with an undisclosed funding round.
Cancer Research and Biotechnology AG is a Swiss preclinical oncology company focusing on metabolic diseases and mitochondrial healing for cancer treatments. CRB is developing new-generation cancer treatments that selectively eradicate cancer cells without inducing toxicity.
Copyright © 2024 DON Therapeutics - All Rights Reserved.
DON THERAPEUTICS LTD is not a Registered Investment Advisor, Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker or Financial Planner. The Information on this 1. Company email, 2 Company Site, 3 Company LinkedIn is provided for information purposes only. The Information is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to you. Before using the Company’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence. None of the information on our email, website, or LinkedIn is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. The Company is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.
Powered by DON Therapeutics